Biology
Inflammation as a Performance Variable: The Metric Most Executives Have Never Tracked
6 min read
Inflammation is the body’s primary defence mechanism. Acute inflammation — the redness, swelling, and heat that follows an injury or infection — is beneficial and necessary. It activates repair processes, fights pathogens, and resolves once the threat is addressed.
Chronic low-grade inflammation is different in kind. It is not a response to a specific threat. It is a persistent background state of immune activation — detectable in the blood, with no obvious cause, producing no dramatic symptoms, but exerting a steady drag on cognitive function, energy, recovery capacity, and long-term health.
In the high-performing executive population, it is remarkably common. And almost universally untracked.
What chronic inflammation does to performance
The brain is exquisitely sensitive to inflammatory signals. Cytokines — the molecular messengers produced by the immune system during inflammatory states — cross the blood-brain barrier and directly influence neurotransmitter function, neuroplasticity, and the activity of brain regions involved in executive function and mood.
The cognitive effects of chronic low-grade inflammation are subtle but consistent: slightly slower processing speed, reduced working memory capacity, lower cognitive flexibility, and a bias toward threat-detection over reward-seeking that narrows strategic thinking. These are not the symptoms of an illness. They are the background condition of a system operating under chronic biological stress.
Energy is affected through multiple pathways. Inflammatory cytokines directly suppress mitochondrial efficiency — reducing the cellular energy production that underlies physical and cognitive stamina. They also dysregulate the HPA axis, elevating cortisol and disrupting the hormonal environment that supports recovery.
Recovery is impaired because the repair processes that restore capacity — muscle protein synthesis, neural consolidation, hormonal repletion — are competing with an immune system in a state of ongoing low-level activation. The body cannot fully invest in rebuilding when it believes it is still managing a threat.
What drives it in the executive population
The drivers of chronic inflammation are well-established. Sleep deprivation is among the most potent: a single night of fewer than six hours of sleep produces a significant transient increase in inflammatory markers. Chronic sleep restriction produces chronically elevated inflammation.
Psychological stress activates the same inflammatory pathways as physical infection. The sustained stress load carried by most executives — responsibility, uncertainty, high cognitive demand, inadequate recovery — is a significant driver of inflammatory elevation that most health assessments completely miss.
Dietary patterns play a significant role: specifically, the combination of high ultra-processed food intake, low dietary fibre, and excess alcohol that characterises the practical eating habits of many high-performing, time-pressured individuals. None of these are extreme. Together, they produce a consistent inflammatory stimulus.
Excess adipose tissue — particularly visceral fat — is itself metabolically active, producing cytokines continuously. Body composition change is one of the most powerful long-term levers for reducing baseline inflammation, independent of diet or exercise effects.
How to measure it
High-sensitivity CRP (hsCRP) is the standard clinical marker for systemic inflammation. The reference range typically considers anything below 10 mg/L as normal. For the purposes of performance optimisation, this is far too broad. Values above 1 mg/L are associated with measurable cognitive and cardiovascular effects. Values above 3 mg/L represent meaningfully elevated risk.
In standard annual health panels, hsCRP is frequently omitted entirely, or measured at standard sensitivity rather than high sensitivity — a different and far less useful test.
Homocysteine is the second marker we consistently prioritise. It is an independent inflammatory and cardiovascular risk marker that is almost universally absent from routine testing, responds well to targeted nutritional intervention (specifically methylated B vitamins), and predicts cardiovascular and cognitive risk with strong evidence.
Fasting insulin and HOMA-IR are metabolic markers with a strong inflammatory dimension — insulin resistance and inflammation are bidirectionally related, each worsening the other.
Together, these four markers — hsCRP, homocysteine, fasting insulin, HOMA-IR — provide a picture of inflammatory and metabolic status that is simply not available from standard annual health testing.
Why it matters over decades
Chronic inflammation is one of the strongest predictors of biological aging rate. It accelerates the deterioration of the cardiovascular system, the brain, and the musculoskeletal system simultaneously. It is the biological mechanism behind many of the conditions associated with aging that most people accept as inevitable.
It is also, in most cases, modifiable. The inflammatory load carried by most executives is not primarily genetic. It is produced by sleep, stress, diet, body composition, and recovery practices — all of which are measurable and addressable. The executives we work with who most dramatically shift their performance trajectory over 12 to 18 months almost always begin with inflammation as one of the first variables to change.